The relatively lower weight loss of setmelanotide-treated BBS patients compared to setmelanotide-treated patients suffering from mutations in the leptin–melanocortin pathway could be explained by the fact that BBS obesity etiology is not entirely known. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.